Bellevue Healthcare (LON:BBH) Trading Down 0.9% - What's Next?

Key Points

• Bellevue Healthcare's stock price decreased by 0.9%, trading at GBX 115.60 ($1.58) with a significantly lower trading volume of 890,112 shares.
• The company reported a negative P/E ratio of -440.88, a negative return on equity of 4.48%, but a >strong>net margin of 169.10%.
• Bellevue Healthcare Trust aims to pay a total dividend of 3.5 pence per ordinary share, mainly from capital, with the same percentage targeted for future financial years.

Bellevue Healthcare (LON:BBH - Get Free Report)'s stock price traded down 0.9% during mid-day trading on Tuesday . The company traded as low as GBX 115.40 ($1.58) and last traded at GBX 115.60 ($1.58). 890,112 shares were traded during trading, a decline of 58% from the average session volume of 2,102,039 shares. The stock had previously closed at GBX 116.60 ($1.59).

Bellevue Healthcare Trading Down 0.9%

The stock has a 50 day moving average of GBX 115.86 and a 200-day moving average of GBX 119.25. The company has a market capitalization of £151.59 million and a P/E ratio of -440.88.

Bellevue Healthcare (LON:BBH - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported GBX 0.19 earnings per share (EPS) for the quarter. Bellevue Healthcare had a negative return on equity of 4.48% and a net margin of 169.10%.

Bellevue Healthcare Company Profile

Bellevue Healthcare Trust plc is a high conviction, long-only investment trust invested in listed or quoted global healthcare equities. It is unconstrained and able to invest regardless of market cap, sub sector or region, and the portfolio is concentrated with a maximum of 35 holdings. The target total dividend in the first financial period is 3.5 pence per ordinary share (to be paid mostly out of capital) and in subsequent financial years will be set at 3.5 per cent.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.